A.T.S. Pharmaceuticals, A Division of Auriga Laboratories, Launches Zytopic(TM) Cream for the Treatment of Atopic Dermatitis

LOS ANGELES, Oct 31, 2007 (BUSINESS WIRE) - Auriga Laboratories, Inc. (OTCBB:ARGA), a specialty pharmaceutical company building the first nationwide, commission-only pharmaceutical sales force, announced today the launch of Zytopic(TM) Cream convenience kit that contains Zytopic(TM) Cream (triamcinolone, USP 0.1%), as well as Clere(TM), a soap free cleanser, and Emolene(TM), a hypoallergenic moisturizer. The introduction of this brand adds to the current ATS portfolio which also includes Akurza(TM) Cream & Lotion (Salicylic Acid 6%), and the brand Xyralid(TM) (lidocaine HCl /hydrocortisone acetate) brand.

Zytopic(TM) Cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, such as atopic dermatitis. Clere(TM) is a hypoallergenic (no perfumes or dyes) cleanser to help manage pruritic conditions. Many cleansers contain detergents, perfumes, dyes and other allergens that further irritate sensitive skin commonly seen in atopic patients. Emolene(TM) is a hypoallergenic cleansing moisturizer also included in the Zytopic(TM) Cream Convenience Kit. Zytopic(TM) Cream will be promoted to dermatologists and primary care practitioners by the ATS Pharmaceutical division of Auriga.

The atopic dermatitis market, and the triamcinolone 0.1% segment, offers ATS the greatest sales opportunity to date. Over five million triamcinolone prescriptions are written on an annual basis according to Wolter Kluwers Health Data, generating estimated sales of over $36 million in the U.S. annually. "In addition, US treatment guidelines recommend the use of hypoallergenic emollients and soap-free cleansers as part of atopic dermatitis treatment regimens. The bundling of these three products into a convenience kit may assist patients to better comply with their physician's directions," said Philip S. Pesin, CEO of Auriga.

Zytopic(TM) Cream is contraindicated in patients with a history of hypersensitivity to any of the components of the lotion. Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria.

SOURCE: Auriga Laboratories, Inc.